N-(tert-butoxycarbonyl) isopropylsulfonamide | 256532-43-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: N-(tert-butoxycarbonyl) isopropylsulfonamide
• 英文别名: tert-butyl N-(propane-2-sulfonyl)carbamate；tert-butyl N-propan-2-ylsulfonylcarbamate
• CAS: 256532-43-1
• 化学式: C₈H₁₇NO₄S
• 分子量: 223.293
• InChiKey: ZRIVPYNVZHZTAC-UHFFFAOYSA-N

物化性质

• 密度：
  1.148±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  80.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(tert-butoxycarbonyl) isopropylsulfonamide 在 三氟乙酸 作用下， 以 水 为溶剂， 反应 0.5h， 以96%的产率得到异丙基磺酰胺
  参考文献：
  名称：

  A reversible safety-catch method for the hydrogenolysis of N-benzyl moieties

  摘要：

  The benzyl groups of beta-hydroxy-N-benzyl sulfonamides are labile toward hydrogenolysis-unlike N-benzyl sulfonamides lacking the beta-hydroxy moiety. We find that N-acyl-N-benzyl sulfonamides undergo hydrogenolysis under very mild conditions. Based upon these observations, we developed a reversible safety-catch method using tert-butoxycarbonyl moieties to activate N-benzyl sulfonamides toward hydrogenolysis. We also explored the utility of the safety-catch activation method for other nitrogen-based functionality such as N-benzyl carboxamides, imides, and related functionality. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2004.09.118
• 作为产物：
  描述：

  N-benzyl N-(tert-butoxycarbonyl) iso-propylsulfonamide 在 palladium dihydroxide 氢气 作用下， 以 乙醇 为溶剂， 以98%的产率得到N-(tert-butoxycarbonyl) isopropylsulfonamide
  参考文献：
  名称：

  A reversible safety-catch method for the hydrogenolysis of N-benzyl moieties

  摘要：

  The benzyl groups of beta-hydroxy-N-benzyl sulfonamides are labile toward hydrogenolysis-unlike N-benzyl sulfonamides lacking the beta-hydroxy moiety. We find that N-acyl-N-benzyl sulfonamides undergo hydrogenolysis under very mild conditions. Based upon these observations, we developed a reversible safety-catch method using tert-butoxycarbonyl moieties to activate N-benzyl sulfonamides toward hydrogenolysis. We also explored the utility of the safety-catch activation method for other nitrogen-based functionality such as N-benzyl carboxamides, imides, and related functionality. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2004.09.118

文献信息

• An asymmetric oxidative cyclization/Mannich-type addition cascade reaction for direct access to chiral pyrrolidin-3-ones
  作者：Su Zhou、Xiongda Xie、Xinxin Xu、Shanliang Dong、Wenhao Hu、Xinfang Xu

  DOI：10.1039/d1cc04830a

  日期：——

  gold and chiral phosphoric acid cooperatively catalyzed enantioselective oxidative cyclization/Mannich-type addition reaction of homopropargyl amides with nitrones has been developed, which provides chiral pyrrolidin-3-ones in high yields with excellent enantioselectivities under mild conditions. This reaction employed stable and readily available alkynes as non-diazo carbene precursors, which provides

  已经开发出一种高效的金和手性磷酸协同催化高炔丙基酰胺与硝酮的对映选择性氧化环化/曼尼希型加成反应，在温和的条件下以高产率提供具有优异对映选择性的手性吡咯烷-3-酮。该反应使用稳定且容易获得的炔烃作为非重氮卡宾前体，提供了一种具有高成键效率的 100% 原子经济方法。
• Sulphonamide derivatives
  申请人：Eli Lilly and Company

  公开号：US06358981B1

  公开（公告）日：2002-03-19

  The present invention relates to the potentiation of glutamate receptor function using certain sulphonamide derivatives. It also relates to novel sulphonamide derivatives, to processes for their preparation and to pharmaceutical compositions containing them.

  本发明涉及使用某些磺胺衍生物增强谷氨酸受体功能。它还涉及新型磺胺衍生物，以及它们的制备方法和含有它们的药物组合物。
• [EN] SUBSTITUTED SULFONAMIDE-CHROMAN COMPOUNDS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS DE SULFONAMIDE-CHROMANE SUBSTITUÉS, COMPOSITIONS PHARMACEUTIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：SUNOVION PHARMACEUTICALS INC

  公开号：WO2022217248A1

  公开（公告）日：2022-10-13

  Provided herein are compounds, pharmaceutical compositions, and methods of use thereof, including methods of treating neurological disorders. For example, provided herein is a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein values for the variables (e.g., X1, R1A, R1B, R2A, R2B, R3A, R3B, R3C, R3D) are as disclosed herein. The compounds disclosed herein (e.g., compounds of Formula I, or pharmaceutically acceptable salts thereof) and pharmaceutical compositions can be used to treat neurological disorders.

  本文提供了化合物、药物组合物及其使用方法，包括治疗神经系统疾病的方法。例如，本文提供了公式I的化合物或其药学上可接受的盐，其中变量的值（例如X1、R1A、R1B、R2A、R2B、R3A、R3B、R3C、R3D）如本文所披露。本文披露的化合物（例如公式I的化合物或其药学上可接受的盐）和药物组合物可用于治疗神经系统疾病。
• PYRROLOPYRIMIDINE DERIVATIVE HAVING ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE INHIBITORY ACTIVITY AND USE THEREOF
  申请人：KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

  公开号：US20220411420A1

  公开（公告）日：2022-12-29

  Disclosed is a novel pyrrolopyrimidine derivative compound, a tautomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a stereoisomer thereof, associated with a compound for inhibiting ENPP1, a composition for inhibiting ENPP1, and a method of inhibiting ENPP1.
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS<br/>[FR] COMPOSITIONS ET MÉTHODES POUR LE TRAITEMENT DU VIRUS RESPIRATOIRE SYNCYTIAL
  申请人：CIDARA THERAPEUTICS INC

  公开号：WO2021050612A1

  公开（公告）日：2021-03-18

  Compositions and methods for the treatment of viral infections include conjugates containing inhibitors of viral RSV F protein (e.g., Presatovir, MDT 637, JNJ 179, TMC353121, Ziresovir, or an analog thereof) linked to an Fc monomer, an Fc domain, and Fc-binding peptide, an albumin protein, or albumin-binding peptide. In particular, conjugates can be used in the treatment of viral infections (e.g., RSV infections).